Angela Cioffi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1576558/publications.pdf

Version: 2024-02-01

27 papers 2,101 citations

331670 21 h-index 25 g-index

28 all docs 28 docs citations

28 times ranked

2795 citing authors

#	Article	IF	CITATIONS
1	Longâ€term outcome of dasatinib firstâ€line treatment in gastrointestinal stromal tumor: A multicenter, 2â€stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07). Cancer, 2018, 124, 1449-1454.	4.1	32
2	A phase II study of regorafenib in patients with thymic epithelial tumours previously treated with chemotherapy Journal of Clinical Oncology, 2018, 36, 8579-8579.	1.6	3
3	Age-Stratified Risk of Unexpected Uterine Sarcoma Following Surgery for Presumed Benign Leiomyoma. Oncologist, 2015, 20, 433-439.	3.7	59
4	Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. European Journal of Cancer, 2015, 51, 852-860.	2.8	23
5	GI Stromal Tumors: 15 Years of Lessons From a Rare Cancer. Journal of Clinical Oncology, 2015, 33, 1849-1854.	1.6	41
6	Tenosynovial giant cell tumour/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors. European Journal of Cancer, 2015, 51, 210-217.	2.8	97
7	Consumptive Coagulopathy in Angiosarcoma: A Recurrent Phenomenon?. Sarcoma, 2014, 2014, 1-7.	1.3	13
8	The mechanistic target of rapamycin pathway in sarcomas: from biology to therapy. Expert Opinion on Orphan Drugs, 2014, 2, 653-664.	0.8	0
9	Malignant Peripheral Nerve Sheath Tumors. Oncologist, 2014, 19, 193-201.	3.7	258
10	Clinical activity of sunitinib in patients with advanced desmoplastic round cell tumor: a case series. Targeted Oncology, 2013, 8, 211-213.	3.6	47
11	Sorafenib in patients with progressive epithelioid hemangioendothelioma. Cancer, 2013, 119, 2639-2644.	4.1	97
12	Angiosarcomas and Other Sarcomas of Endothelial Origin. Hematology/Oncology Clinics of North America, 2013, 27, 975-988.	2.2	32
13	Genetic Profiling Identifies Two Classes of Soft-Tissue Leiomyosarcomas with Distinct Clinical Characteristics. Clinical Cancer Research, 2013, 19, 1190-1196.	7.0	46
14	Primary adrenal angiosarcoma and functioning adrenocortical adenoma: an exceptional combined tumor. European Journal of Endocrinology, 2012, 166, 131-135.	3.7	19
15	Randomized Multicenter and Stratified Phase II Study of Gemcitabine Alone Versus Gemcitabine and Docetaxel in Patients with Metastatic or Relapsed Leiomyosarcomas: A Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist, 2012, 17, 1213-1220.	3.7	182
16	Clinical and pharmacokinetic evaluation of trabectedin for the treatment of soft-tissue sarcoma. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 113-122.	3.3	4
17	Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer, 2012, 118, 3330-3336.	4.1	118
18	Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib. Annals of Surgical Oncology, 2012, 19, 1551-1559.	1.5	57

#	Article	IF	CITATIONS
19	Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy. Cancer Chemotherapy and Pharmacology, 2012, 69, 357-367.	2.3	32
20	Quantitative functional imaging by Dynamic Contrast Enhanced Ultrasonography (DCE-US) in GIST patients treated with masatinib. Investigational New Drugs, 2012, 30, 765-771.	2.6	57
21	Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma. European Journal of Cancer, 2011, 47, 515-519.	2.8	72
22	Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncology, The, 2011, 12, 1045-1052.	10.7	212
23	Treating soft tissue sarcomas with adjuvant chemotherapy. Current Treatment Options in Oncology, 2011, 12, 21-31.	3.0	53
24	Phase II study of oral masitinib mesilate in imatinib-naÃ-ve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). European Journal of Cancer, 2010, 46, 1344-1351.	2.8	118
25	Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncology, The, 2010, 11, 942-949.	10.7	260
26	Stratégie de prise en charge des tumeurs primitives. Revue Du Rhumatisme (Edition Francaise), 2008, 75, 362-368.	0.0	0
27	Docetaxel and gemcitabine combination in 133 advanced softâ€tissue sarcomas: A retrospective analysis. International Journal of Cancer, 2006, 119, 706-711.	5.1	169